Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial

about

Dopamine D2 -141C Ins/Del and Taq1A polymorphisms, body mass index, and prediction error brain response.

P2860

Q55282471-E5D57B0F-4CC8-4A47-8291-907C8B75BB48

P2860

Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial

Item

http://www.wikidata.org/entity/Q36377903

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Dopamine D2/3 Receptor Occupan ...... : An Open-Label Clinical Trial

@ast

Dopamine D2/3 Receptor Occupan ...... : An Open-Label Clinical Trial

@en

type

Item

label

Dopamine D2/3 Receptor Occupan ...... : An Open-Label Clinical Trial

@ast

Dopamine D2/3 Receptor Occupan ...... : An Open-Label Clinical Trial

@en

prefLabel

Dopamine D2/3 Receptor Occupan ...... : An Open-Label Clinical Trial

@ast

Dopamine D2/3 Receptor Occupan ...... : An Open-Label Clinical Trial

@en

P1476

Dopamine D2/3 Receptor Occupan ...... : An Open-Label Clinical Trial

@en

P2093

Benoit H Mulsant

http://www.w3.org/2001/XMLSchema#string

Bruce G Pollock

http://www.w3.org/2001/XMLSchema#string

David C Mamo

http://www.w3.org/2001/XMLSchema#string

Eric Plitman

http://www.w3.org/2001/XMLSchema#string

Fernando Caravaggio

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Uchida

http://www.w3.org/2001/XMLSchema#string

Philip Gerretsen

http://www.w3.org/2001/XMLSchema#string

Robert R Bies

http://www.w3.org/2001/XMLSchema#string

Shinichiro Nakajima

http://www.w3.org/2001/XMLSchema#string

Takefumi Suzuki

http://www.w3.org/2001/XMLSchema#string

P2860

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.

Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study.

Using antipsychotic agents in older patients.

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

P304

212-219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/SCHBUL/SBV106

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ariel Graff-Guerrero

P577

2015-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26221049

http://www.w3.org/2001/XMLSchema#string

P921

dopamine

P932

4681559

http://www.w3.org/2001/XMLSchema#string

Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial

about

P2860

P2860

Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932